Litigation Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

« Back to Dashboard

Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Docket		Date Filed	2015-09-04
Court	District Court, D. Delaware	Date Terminated	2018-04-24
Cause	35:271 Patent Infringement	Assigned To	Timothy Belcher Dyk
Jury Demand	None	Referred To
Patents	6,733,783; 8,361,499; 8,529,948; 8,551,520; 8,647,667; 8,808,740; 9,023,401; 9,056,052; 9,060,940
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-09-04				External link to document
2015-09-04	17		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,056,052; 9,060,940. (Attachments…2015 24 April 2018 1:15-cv-00784 830 Patent None District Court, D. Delaware	External link to document
2015-09-04	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,056,052; 9,060,940; (aah) (Entered…2015 24 April 2018 1:15-cv-00784 830 Patent None District Court, D. Delaware	External link to document

Purdue Pharma v. Alvogen Pine Brook: Litigation Summary and Patent Analysis, 1:15-cv-00784

Last updated: August 27, 2026

Purdue Pharma L.P. sued Alvogen Pine Brook LLC in the U.S. District Court for the District of Delaware after Alvogen filed an abbreviated new drug application seeking approval for a generic version of Hysingla ER, Purdue's extended-release hydrocodone product. The case was a Hatch-Waxman patent action under 35 U.S.C. § 271(e)(2). The dispute centered on Purdue's abuse-deterrent, controlled-release hydrocodone formulation patents and the timing of generic entry.

What drug and patents were involved in Purdue v. Alvogen?

The case concerned Hysingla ER, an extended-release tablet containing hydrocodone bitartrate. Purdue markets Hysingla ER for the management of pain severe enough to require a daily, around-the-clock, long-term opioid analgesic when alternative treatments are inadequate.[1]

Alvogen's ANDA challenged Purdue's Orange Book-listed patents through Paragraph IV certifications. Purdue responded by asserting patent infringement based on the filing of the ANDA.

Item	Case information
Plaintiff	Purdue Pharma L.P.
Defendant	Alvogen Pine Brook LLC
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-00784
Legal pathway	Hatch-Waxman ANDA litigation
Product	Hysingla ER
Active ingredient	Hydrocodone bitartrate
Dosage form	Extended-release abuse-deterrent tablet
Regulatory trigger	Paragraph IV ANDA certification
Primary commercial issue	Timing and conditions of generic Hysingla ER entry

The principal patent family covered controlled-release and abuse-deterrent opioid dosage forms. Purdue's Hysingla ER patent estate included U.S. Patent Nos. 8,337,888 and 8,808,316, together with later-issued continuation or related patents listed for the product in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[2]

What patents protect Hysingla ER?

Purdue's Hysingla ER protection was built around formulation architecture rather than hydrocodone as a molecule. Hydrocodone itself is an established active pharmaceutical ingredient and does not provide the principal patent barrier for a generic entrant.

The relevant patent claims generally addressed:

• A hydrocodone-containing controlled-release matrix.
• High-viscosity polymer systems, including polyethylene oxide-based matrices.
• Release profiles designed to provide extended analgesic exposure.
• Physical properties intended to make crushing, grinding, or extraction more difficult.
• Abuse-deterrent performance characteristics.
• Dosage forms and manufacturing parameters associated with the finished tablet.

U.S. Patent No. 8,337,888 was directed to controlled-release opioid dosage forms and was among the key patents associated with Hysingla ER. U.S. Patent No. 8,808,316 represented a later patent in the same broader Purdue controlled-release and abuse-deterrence portfolio.[2]

The case therefore involved formulation and product-by-process issues, not a conventional compound-patent dispute. That distinction affected both the infringement analysis and Alvogen's invalidity defenses. A generic applicant could potentially avoid infringement by changing polymer concentrations, tablet structure, manufacturing conditions, or release characteristics, although those changes could also affect FDA approval and therapeutic equivalence.

How did the Paragraph IV challenge affect the litigation?

Under the Hatch-Waxman statute, Alvogen's Paragraph IV certification asserted that the relevant Purdue patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Purdue's lawsuit triggered the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.

The filing of the action prevented FDA approval of the challenged ANDA during the initial stay period unless the litigation ended earlier or the court entered a qualifying decision. The case thus created a regulatory standstill even before a commercial launch could occur.

The litigation sequence was typical of a Paragraph IV case:

1. Alvogen filed an ANDA for generic extended-release hydrocodone.
2. Alvogen sent Purdue a Paragraph IV notice.
3. Purdue filed the Delaware infringement action.
4. The parties litigated claim construction, infringement, validity, and regulatory timing.
5. The case was resolved before an unrestricted generic launch based solely on the ANDA filing.

The ANDA filing itself was treated as an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing Purdue to litigate patent rights before the generic product entered the market.

What was the litigation status and outcome?

The case was resolved through a negotiated disposition rather than a publicly reported trial judgment invalidating Purdue's Hysingla ER patent estate. The public docket reflects a Hatch-Waxman dispute that did not produce a Federal Circuit merits decision establishing that the asserted Purdue patents were invalid or not infringed.[3]

The practical result was that Alvogen did not obtain an immediate unrestricted market-entry right through a merits victory. Any generic entry rights depended on the terms of the parties' resolution and on FDA approval of the relevant ANDA.

Issue	Outcome
ANDA litigation	Filed and litigated in Delaware
Paragraph IV challenge	Yes
Purdue patent claims	Directed primarily to controlled-release and abuse-deterrent formulations
Public merits holding	No controlling appellate merits decision reported for this action
Generic entry	Governed by the negotiated resolution and applicable regulatory approvals
Immediate invalidation of Purdue estate	No
Permanent injunction after trial	No publicly reported trial injunction establishing a final merits monopoly
Commercial effect	Delayed and conditioned generic competition

The absence of a published merits opinion is material. A settlement does not establish that the asserted patents were valid, infringed, or enforceable. It also does not provide a legal precedent for other ANDA applicants. The commercial effect can still be substantial because settlement terms may establish a negotiated launch date, license conditions, supply arrangements, or other restrictions.

When did Hysingla ER lose exclusivity?

Hysingla ER did not lose all exclusivity on a single date. FDA exclusivity and patent exclusivity operate separately.

Hysingla ER was approved by FDA in November 2014 as an abuse-deterrent extended-release hydrocodone product.[1] The product received five-year new chemical entity exclusivity, subject to the statutory rules applicable to hydrocodone. That regulatory exclusivity period was separate from the Orange Book patent term.

The patent estate extended beyond the initial regulatory exclusivity period. The principal patents listed for Hysingla ER had expiration dates in the early 2030s, subject to patent-term adjustment, terminal disclaimers, pediatric exclusivity, and any changes to Orange Book listings.[2]

Exclusivity layer	Effect
FDA approval	Established Hysingla ER as an approved reference drug
NCE exclusivity	Restricted certain ANDA submissions during the statutory exclusivity period
Orange Book patents	Created infringement exposure for ANDA applicants
Paragraph IV certification	Allowed generic applicants to challenge listed patents before launch
Patent settlement	Could authorize entry before patent expiration under negotiated conditions
Abuse-deterrent formulation patents	Protected product design even though hydrocodone itself was not new

Patent expiration alone did not guarantee immediate market entry. A generic applicant still required FDA approval, satisfactory bioequivalence, compliance with controlled-substance requirements, and resolution of any remaining listed patents or regulatory barriers.

What was the Orange Book status of Hysingla ER?

The Orange Book listed Purdue-related patents for Hysingla ER covering the product's formulation and controlled-release characteristics.[2] Orange Book listings are commercially significant because they determine which patent certifications an ANDA applicant must make.

For a product such as Hysingla ER, the Orange Book analysis requires separating:

• Drug-substance patents.
• Drug-product formulation patents.
• Method-of-use patents.
• Patents claiming abuse-deterrent characteristics.
• Later-issued continuation patents.
• Patents that may have been delisted, expired, or replaced over time.

The listed patents did not necessarily cover every hydrocodone extended-release product. Their scope depended on the asserted claim language, the generic's formulation, and the court's construction of technical terms involving polymer matrices, release rates, tablet hardness, and abuse-deterrent properties.

What patent defenses could Alvogen assert?

Alvogen's defenses would have been evaluated claim by claim. The main defenses in a formulation-based Hatch-Waxman case are the following.

Noninfringement

Alvogen could argue that its proposed product did not meet one or more limitations of the asserted claims. Potential disputes included polymer composition, molecular weight, drug loading, tablet structure, release profile, and manufacturing conditions.

A generic applicant does not need to reproduce the reference product exactly. It needs to satisfy FDA requirements for the proposed product. That creates room for formulation design-around arguments, although the proposed product remains exposed if it falls within the literal scope or doctrine-of-equivalents scope of the patent claims.

Invalidity

Alvogen could challenge the patents under 35 U.S.C. §§ 102 and 103 for anticipation or obviousness. Prior-art references could include earlier controlled-release hydrocodone products, opioid matrix formulations, polymer science publications, and Purdue's own earlier opioid patents.

Obviousness was likely the central technical risk. The patents combined known components, but Purdue's position depended on whether the claimed combination produced a predictable release profile and sufficient abuse-deterrent performance.

Written description and enablement

Alvogen could also challenge whether the patent specifications supported the full breadth of the claims and enabled the claimed formulations without undue experimentation. These defenses are relevant when broad claims cover many polymer types, drug concentrations, and release profiles but the specification provides limited working examples.

Unenforceability

An inequitable-conduct defense would require clear and convincing evidence of material misrepresentation or omission with specific intent to deceive the U.S. Patent and Trademark Office. Such a defense generally presents a high litigation burden and would not be established by ordinary prosecution errors.

How strong was Purdue's patent estate?

Purdue's estate was commercially meaningful but structurally narrower than a new-molecule patent estate. Its strength came from multiple formulation claims, Orange Book listing, regulatory delay, and the difficulty of developing a bioequivalent abuse-deterrent product.

Strength factor	Assessment
Active ingredient protection	Limited because hydrocodone was established
Formulation protection	Significant
Abuse-deterrence protection	Significant but technically dependent
Design-around exposure	Moderate to high
Orange Book leverage	High during the protected period
Litigation leverage	Strong because the ANDA triggered a 30-month stay
Patent invalidity exposure	Meaningful because formulation claims often combine known technologies
Manufacturing barrier	Moderate; reproducing release and abuse-deterrent specifications can be difficult
Biosimilar relevance	None; Hysingla ER is a small-molecule drug

The estate's commercial value depended on whether competing manufacturers could develop an extended-release hydrocodone product that satisfied FDA requirements without practicing the asserted claims. A design-around might avoid infringement but still face bioequivalence and abuse-deterrence testing challenges.

Did biosimilar risk apply to Hysingla ER?

No. Hysingla ER is a small-molecule drug, not a biologic. Competitors must file ANDAs rather than biosimilar applications under the Public Health Service Act.

The relevant competitive risks were:

• Paragraph IV generic challenges.
• Authorized generic arrangements.
• Formulation design-arounds.
• Therapeutic-equivalence approval.
• Controlled-substance manufacturing and distribution compliance.

Biosimilar interchangeability, reference-product exclusivity under the Biologics Price Competition and Innovation Act, and biologic patent dance procedures did not apply.

What generic launch scenarios existed after the case?

Three launch scenarios were commercially relevant.

Entry after negotiated settlement

A settlement could authorize Alvogen to launch on a specified date before patent expiration. The agreement could also include a license, supply arrangement, or restrictions on the product configuration.

Entry after patent expiry

Alvogen could launch after the relevant listed patents expired, provided FDA approval was available and no other patents or regulatory issues blocked approval.

At-risk launch

Alvogen could launch before final resolution of patent disputes, accepting potential damages and injunction risk. This scenario was less attractive where Purdue held multiple formulation patents and the product involved a controlled substance.

The settlement route was the most likely commercial pathway because it avoided the cost and uncertainty of a full trial while preserving Purdue's ability to delay or control generic entry.

What licensing deals or settlement agreements affected the case?

The publicly available court record does not establish a broad cross-company license comparable to a platform transaction. The case's commercial significance arose from the settlement of the specific ANDA dispute rather than from a disclosed licensing deal transferring Purdue's entire opioid formulation portfolio.

Hatch-Waxman settlements require antitrust scrutiny under the Federal Trade Commission Act and the Medicare Prescription Drug, Improvement, and Modernization Act reporting framework. A settlement's competitive effect depends on:

• The agreed generic entry date.
• Whether Alvogen received a license to Purdue patents.
• Whether Purdue supplied product to Alvogen.
• Whether the agreement included compensation or other consideration.
• Whether the settlement restricted future generic development.
• Whether the agreement preserved or waived claims against later Alvogen products.

A dismissal alone does not reveal all commercial terms. The operative settlement agreement, if filed under seal or reported only in regulatory submissions, may provide more detail than the public docket.

How does this case compare with other Hysingla ER challenges?

Purdue faced multiple ANDA challenges to Hysingla ER from generic manufacturers. The competitive pattern was different from litigation over a single active-ingredient patent.

Issue	Hysingla ER litigation	Conventional small-molecule compound case
Main patent subject	Formulation and abuse deterrence	Active pharmaceutical ingredient
Design-around potential	Higher	Often lower
Technical proof	Release testing, polymer matrix, abuse-deterrence data	Chemical identity and synthesis
Generic product	Must match extended-release performance	Usually conventional dosage form
Patent estate	Multiple related formulation patents	Often one principal compound patent
Biosimilar pathway	Not applicable	Not applicable
Commercial uncertainty	High because formulation changes affect approval	Lower where compound identity is fixed

The Alvogen case should therefore be analyzed together with the broader Hysingla ER patent family and competing ANDA cases. A favorable result for Purdue in one action would not automatically establish infringement by every generic applicant because each ANDA formulation and certification can differ.

Key Takeaways

• Purdue sued Alvogen in Delaware over an ANDA for generic Hysingla ER.
• The case was a Paragraph IV Hatch-Waxman action involving extended-release hydrocodone bitartrate.
• Purdue's protection centered on controlled-release and abuse-deterrent formulation patents, including U.S. Patent Nos. 8,337,888 and 8,808,316.
• Hydrocodone itself was not the principal source of patent exclusivity.
• The litigation created a statutory FDA approval delay and exposed Alvogen to infringement liability under 35 U.S.C. § 271(e)(2).
• The public record does not establish a final Federal Circuit merits ruling invalidating Purdue's Hysingla ER patents.
• Generic entry was governed by the negotiated disposition, FDA approval, and remaining patent rights.
• Biosimilar law did not apply because Hysingla ER is a small-molecule drug.
• Purdue's estate had meaningful commercial strength but remained exposed to formulation design-arounds and invalidity attacks based on prior controlled-release technologies.

FAQs

What was Alvogen's generic product in the Purdue lawsuit?

Alvogen's ANDA concerned a proposed generic version of Hysingla ER, an extended-release hydrocodone bitartrate tablet with abuse-deterrent characteristics.

Was Purdue's Hysingla ER compound patent at issue?

The principal dispute concerned formulation and controlled-release technology. Hydrocodone was an established drug substance, so Purdue's protection focused on the dosage form rather than a new hydrocodone molecule.

Could Alvogen launch generic Hysingla ER before Purdue's patent expiration?

Only if the settlement authorized an earlier launch, the asserted patents were removed as barriers, or Alvogen proceeded at risk. FDA approval alone would not eliminate patent infringement exposure.

Does the case create precedent for other Hysingla ER ANDA applicants?

No broad precedent follows from a private settlement or dismissal. Other applicants remained subject to separate patent claims, product formulations, and litigation outcomes.

Did Purdue's bankruptcy eliminate the Hysingla ER patent rights?

No. Bankruptcy proceedings can affect ownership, enforcement, licensing, and settlement authority, but they do not automatically cancel issued patents or Orange Book listings.

References

1. U.S. Food and Drug Administration. (2014). Hysingla ER: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
3. U.S. District Court for the District of Delaware. (2015). Purdue Pharma L.P. v. Alvogen Pine Brook LLC, No. 1:15-cv-00784, docket record.
4. 21 U.S.C. § 355.
5. 35 U.S.C. § 271(e)(2).